A Survey Conducted on Patients' and Urologists' Perceptions of Benign Prostatic Hyperplasia

被引:8
|
作者
Kim, Sun Il [1 ]
Kang, Jung Yoon [2 ]
Lee, Hae Won [3 ]
Seong, Do Hwan [4 ]
Cho, Jin Seon [5 ]
机构
[1] Ajou Univ, Sch Med, Dept Urol, Suwon 441749, South Korea
[2] Eulji Univ, Coll Med, Dept Urol, Seoul, South Korea
[3] Dongguk Univ, Coll Med, Dept Urol, Ilsan, South Korea
[4] Inha Univ, Coll Med, Dept Urol, Inchon, South Korea
[5] Hallym Univ, Coll Med, Dept Urol, Anyang, South Korea
关键词
Benign prostatic hyperplasia; Questionnaire; Pharmacotherapy; Finasteride; FINASTERIDE; MEN;
D O I
10.1159/000323530
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To better understand the discrepancy that may exist between urologists and patients on various aspects of their perception of benign prostatic hyperplasia (BPH). Subjects and Methods: Questionnaires on BPH for patients and urologists and a BPH patient education brochure were developed. 141 patients with symptoms of BPH completed a set of two questionnaires, to be filled out before and after reading the education brochure. 172 urologists practicing in Korea were randomly selected to complete the questionnaire. Results: Nearly 60% of patients misunderstood the risk for BPH to progress to prostate cancer. In addition, the perceived risks of untreated BPH, desirable treatment effects and undesirable side effects were significantly different between the patients and the urologists. Among the discrete attributes of available medical therapy, the 5 alpha-reductase inhibitor monotherapy was the preferred method chosen by patients. Although the patient brochure significantly improved most of the patients' misconceptions about BPH, the patient preference did not change significantly. Conclusions: Patients with BPH do not have accurate information about their disease and their expectations of treatment may be very different from their urologist. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码:278 / 283
页数:6
相关论文
共 50 条
  • [41] Management of benign prostatic hyperplasia
    Barry, M
    Roehrborn, C
    ANNUAL REVIEW OF MEDICINE, 1997, 48 : 177 - 189
  • [42] Silodosin for Benign Prostatic Hyperplasia
    Cantrell, Matthew A.
    Bream-Rouwenhorst, Heather R.
    Hemerson, Phyllis
    Magera, James S., Jr.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (02) : 302 - 310
  • [43] Update on the medical management of benign prostatic hyperplasia
    Manoj Monga
    International Urology and Nephrology, 2002, 33 (1) : 67 - 68
  • [44] Management of benign prostatic hyperplasia by family physicians
    Toguri, Allan
    Barkin, Jack
    CANADIAN JOURNAL OF UROLOGY, 2010, 17 : 26 - 34
  • [45] Doxazosin for the symptomatic treatment of benign prostatic hyperplasia
    Kevin T. McVary
    Current Urology Reports, 2003, 4 (4) : 267 - 268
  • [46] Personalized Medicine for the Management of Benign Prostatic Hyperplasia
    Bechis, Seth K.
    Otsetov, Alexander G.
    Ge, Rongbin
    Olumi, Aria F.
    JOURNAL OF UROLOGY, 2014, 192 (01) : 16 - 23
  • [47] Pharmacotherapy and herbal treatment of benign prostatic hyperplasia
    Sun, Jianming
    Zhang, Xiaoping
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2014, 19 : 789 - 797
  • [48] The mechanism of epristeride against benign prostatic hyperplasia
    Sun, ZY
    Wu, HY
    Wang, MY
    Tu, ZH
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 371 (2-3) : 227 - 233
  • [49] Medical therapy for benign prostatic hyperplasia progression
    McVary K.T.
    Current Urology Reports, 2002, 3 (4) : 269 - 275
  • [50] Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia?
    Ghafar M.A.
    Puchner P.J.
    Anastasiadis A.G.
    Cabelin M.A.
    Buttyan R.
    Current Urology Reports, 2002, 3 (4) : 292 - 296